Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Kura Oncology stock
Own Kura Oncology stock in just a few minutes.
Kura Oncology, Inc is a biotechnology business based in the US. Kura Oncology shares (KURA) are listed on the NASDAQ and all prices are listed in US Dollars. Kura Oncology employs 88 staff and has a market cap (total outstanding shares value) of USD0.00.
How to buy shares in Kura Oncology
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Kura Oncology. Find the stock by name or ticker symbol: KURA. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Kura Oncology reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Kura Oncology, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Kura Oncology. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Kura Oncology share price
Use our graph to track the performance of KURA stocks over time.Kura Oncology shares at a glance
Information last updated 2021-04-15.
| 52-week range | USD$9.8875 - USD$43 |
|---|---|
| 50-day moving average | USD$28.5097 |
| 200-day moving average | USD$33.0625 |
| Wall St. target price | USD$41.63 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-1.568 |
Buy Kura Oncology shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Kura Oncology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Kura Oncology financials
| Gross profit TTM | USD$0 |
|---|---|
| Return on assets TTM | -12.92% |
| Return on equity TTM | -21.61% |
| Profit margin | 0% |
| Book value | $9.229 |
| Market capitalisation | USD$1.9 billion |
TTM: trailing 12 months
Shorting Kura Oncology shares
There are currently 9.2 million Kura Oncology shares held short by investors – that's known as Kura Oncology's "short interest". This figure is 0.5% up from 9.1 million last month.
There are a few different ways that this level of interest in shorting Kura Oncology shares can be evaluated.
Kura Oncology's "short interest ratio" (SIR)
Kura Oncology's "short interest ratio" (SIR) is the quantity of Kura Oncology shares currently shorted divided by the average quantity of Kura Oncology shares traded daily (recently around 811943.47826087). Kura Oncology's SIR currently stands at 11.27. In other words for every 100,000 Kura Oncology shares traded daily on the market, roughly 11270 shares are currently held short.
However Kura Oncology's short interest can also be evaluated against the total number of Kura Oncology shares, or, against the total number of tradable Kura Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kura Oncology's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Kura Oncology shares in existence, roughly 140 shares are currently held short) or 0.1604% of the tradable shares (for every 100,000 tradable Kura Oncology shares, roughly 160 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kura Oncology.
Find out more about how you can short Kura Oncology stock.
Kura Oncology share dividends
We're not expecting Kura Oncology to pay a dividend over the next 12 months.
Kura Oncology share price volatility
Over the last 12 months, Kura Oncology's shares have ranged in value from as little as $9.8875 up to $43. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kura Oncology's is 1.9868. This would suggest that Kura Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Kura Oncology overview
Kura Oncology, Inc. , a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. .
Frequently asked questions
More guides on Finder
-
T. Rowe Price review
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
-
How to buy ZTO Express Cayman stock
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
-
How to buy Zomedica stock
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
-
How to buy ZoomInfo Technologies stock
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
-
How to buy ZK International Group CoLtd stock
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
-
How to buy Zions Bancorporation National Association stock
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
-
How to buy Zentalis Pharmaceuticals stock
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
-
How to buy Yunhong International stock
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
-
How to buy Zealand Pharma A/S stock
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
-
How to buy Yunhong CTI stock
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
Ask an Expert